Vivesto AB (Vivesto AB) Change In Inventory : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Change In Inventory?

Vivesto AB's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Vivesto AB's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Vivesto AB's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Vivesto AB's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Vivesto AB's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Vivesto AB Change In Inventory Historical Data

The historical data trend for Vivesto AB's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Change In Inventory Chart

Vivesto AB Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-0.44

-2.68

4.58

0.05

Vivesto AB Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-0.13	-	-	-	-

Vivesto AB Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Vivesto AB (OTCPK:OASMY) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Vivesto AB's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Vivesto AB's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Vivesto AB's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Vivesto AB Change In Inventory Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivesto AB (Vivesto AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

VIVE:Sweden OMAX:Germany

Address

Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73

Website

https://www.vivesto.com

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.